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Abstract: Astaxanthin is a xanthophyll carotenoid present in microalgae, fungi, complex 
plants, seafood, flamingos and quail. It is an antioxidant with anti-inflammatory properties 
and as such has potential as a therapeutic agent in atherosclerotic cardiovascular disease. 
Synthetic forms of astaxanthin have been manufactured. The safety, bioavailability and 
effects  of  astaxanthin  on  oxidative  stress  and  inflammation  that  have  relevance  to  the 
pathophysiology of atherosclerotic cardiovascular disease, have been assessed in a small 
number of clinical studies. No adverse events have been reported and there is evidence of a 
reduction  in  biomarkers  of  oxidative  stress  and  inflammation  with  astaxanthin 
administration.  Experimental  studies  in  several  species  using  an  ischaemia-reperfusion 
myocardial  model  demonstrated  that  astaxanthin  protects  the  myocardium  when 
administered both orally or intravenously prior to the induction of the ischaemic event. At 
this stage we do not know whether astaxanthin is of benefit when administered after a 
cardiovascular event and no clinical cardiovascular studies in humans have been completed 
and/or reported. Cardiovascular clinical trials are warranted based on the physicochemical 
and antioxidant properties, the safety profile and preliminary experimental cardiovascular 
studies of astaxanthin.  
Keywords: antioxidants; xanthophyll carotenoid; inflammation; Haematococcus pluvialis; 
oxidative stress  
 
OPEN ACCESS Mar. Drugs 2011, 9  
 
 
448 
1. Introduction  
Astaxanthin is a xanthophyll carotenoid of predominantly marine origin, with potent antioxidant 
and anti-inflammatory effects demonstrated in both experimental and human studies. Oxidative stress 
and inflammation are common pathophysiological features of atherosclerotic cardiovascular disease 
hence astaxanthin may have a potential therapeutic role in this condition. This review will summarise 
the available evidence suggesting astaxanthin may be of therapeutic value in cardiovascular disease.  
2. Oxidative Stress and Inflammation  
Oxidative stress and inflammation are established non-traditional risk factors for atherosclerosis 
associated cardiovascular morbidity and mortality [1]. Dietary antioxidants can reduce the oxidation of 
lipids and proteins and have the potential to protect from the development of arterial stiffening and 
atherosclerosis  [2–4].  Cross-sectional  and  prospective  observational  studies  have  demonstrated  an 
association between the intake of dietary antioxidants and/or their plasma levels and a reduction of 
cardiovascular events [5–10]. This supports the theory that oxidative stress is a pathophysiological 
process involved in atherosclerotic vascular damage. Also, a reduced dietary antioxidant intake is 
associated with oxidative stress and inflammation [11]. Newer more potent dietary antioxidants such 
as astaxanthin have yet to be studied in this setting. Studies that have assessed the intake of -carotene 
or dietary -carotene supplementation have shown higher -carotene consumption is associated with a 
reduction  in  cardiovascular  disease  [6,12–17].  Other  than  a  few  studies  [18–20],  cardiovascular 
intervention trials using antioxidants have not demonstrated benefits [21–23]. This may be because 
study participants did not have oxidative stress and/or the antioxidants used were insufficiently potent. 
In  addition,  it  is  becoming  recognized  that  there  is  communication  between  oxidative  stress  and 
inflammatory processes leading to the additional hypothesis that antioxidants may be able to modify 
both  deleterious  events.  Further  research  is  needed  studying  antioxidants  with  different  biological 
actions in patients with demonstrated oxidative stress.  
3. Carotenoids  
Carotenoids are ubiquitous, and found in high concentrations in plants, algae and microorganisms. 
Humans  and  other  animals  cannot  synthesize  them  and  therefore  are  required  to  source  them  in 
their diet [24]. Carotenoids are classified, according to their chemical structure, into carotenes and 
xanthophylls.  The  carotene  carotenoids  include  -carotene  and  lycopene  and  the  xanthophyll 
carotenoids include lutein, canthaxanthin, zeaxanthin, violaxanthin, capsorubin and astaxanthin [25,26].  
The effects of carotenoids vary dependent on how they interact with cell membranes [25]. The 
effects of astaxanthin, zeaxanthin, lutein, -carotene and lycopene on lipid peroxidation have been 
assessed using a polyunsaturated fatty acid enriched membrane model [25,27]. Non-polar carotene 
carotenoids  such  as  lycopene  and -carotene  caused  membrane  disorder  and  lipid  peroxidation  in 
contrast to the polar xanthophyll carotenoid astaxanthin, which preserved membrane structure [27]. 
Contrasting effects of different carotenoids may be responsible for the differing biological effects seen 
in clinical studies. For instance, in some studies the non-polar carotenoid, -carotene has been shown 
to  have  no  benefit  on  cardiovascular  disease  [28–32]  and  in  fact  it  may  be  pro-oxidant  at  high  Mar. Drugs 2011, 9  
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doses [33]. In contrast, the polar carotenoid astaxanthin has protective effects on the cardiovascular 
system  demonstrated  in  animal  studies.  However,  this  has  not  been  studied  in  human  clinical  
trials [34–36]. -carotene at physiological levels may act in differing ways when ultraviolet A light A 
(UVA)  acts  on  keratinocytes  including  vitamin  A-independent  pathways  [37].  Astaxanthin, 
canthaxanthin  and  -carotene  had  differential  effects  on  UVA-induced  oxidative  damage  [38]. 
In addition, carotenoids may also alter the immune response [39] and transcription [40]. 
4. Astaxanthin 
Astaxanthin  contains  two  oxygenated  groups  on  each  ring  structure  (see  Figure  1),  which  is 
responsible for its enhanced antioxidant features [41]. It is found in living organisms particularly in the 
marine environment where it is present in microalgae, plankton, krill and seafood. It gives salmon, 
trout,  and  crustaceans  such  as  shrimp  and  lobster  their  distinctive  reddish  coloration  [42].  It  is  
also present in yeast, fungi, complex plants and the feathers of some birds including flamingos and 
quail [42]. In 1987, the United States Food and Drug Administration approved astaxanthin as a feed 
additive  for  use  in  the  aquaculture  industry  and  in  1999  it  was  approved  for  use  as  a  dietary 
supplement (nutraceutical) [41]. The microalgae Haematococcus pluvialis produces the astaxanthin 
isomer (3S, 3S′), which is the same as the form found in wild salmon. Synthesis of astaxanthin is not 
possible in humans and it cannot be converted to vitamin A, which means excess intake will not cause 
hypervitaminosis A toxicity [43,44]. Astaxanthin and canthaxanthin are scavengers of free radicals, 
chain-breaking antioxidants and potent quenchers of reactive oxygen and nitrogen species including 
singlet oxygen, single and two electron oxidants [45–47]. They (astaxanthin and canthaxanthin) have 
terminal  carbonyl  groups  that  are  conjugated  to  a  polyene  backbone  [26]  and  are  more  potent 
antioxidants and scavengers of free radicals than carotene carotenoids such as -carotene [47,48]. For 
these  reasons  dietary  supplementation  with  astaxanthin  has  the  potential  to  provide  antioxidant 
protection of cells and from atherosclerotic cardiovascular disease [49].  
Figure 1. Molecular structure of astaxanthin. 
 
5. Astaxanthin Formulations 
5.1. Astaxanthin of Marine Origin 
Astaxanthin  used  in  nutritional  supplements  is  usually  a  mixture  of  configurational  isomers 
produced  by  Haematococcus  pluvialis,  a  unicellular  microalga  [50].  Astaxanthin  can  be  produced  
in  its  natural  forms  on  a  large  scale  [51].  The  initial  production  of  astaxanthin  from 
Haematococcus pluvialis  uses  closed  culture  systems  followed  by  a  5–7  day,  “reddening”  cycle, Mar. Drugs 2011, 9  
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conducted in open culture ponds. At each production stage, the cultures are closely monitored by 
microscopic  examination  to  ensure  they  remain  free  of  contamination.  After  the  reddening  cycle, 
Haematococcus pluvialis cultures are harvested, washed and dried. The final step for the production of 
astaxanthin is extraction of dried Haematococcus pluvialis biomass using supercritical carbon dioxide 
to  produce  a  purified  oleoresin,  which  is  free  of  any  contamination.  Other  sources  used  for  the 
commercial  production  of  astaxanthin  include  cultures  of  Euphausia  pacifica  (Pacific  krill), 
Euphausia superba (Antarctic krill), Pandalus borealis (shrimp) and Xanthophyllomyces dendrorhous, 
formerly Phaffia rhodozyma (yeast). Astaxanthin from natural sources varies considerably from one 
organism to another. For instance, the astaxanthin found in seafood will depend on the stereoisomer 
ingested. Astaxanthin produced by haematococcus pluvialis, consists of the (3-S,3′-S) stereoisomer 
which is most commonly used in aquaculture. It is therefore the form most commonly consumed 
by humans. 
5.2. Synthetic Astaxanthin  
There  are  three  stereoisomers  of  astaxanthin;  (3-R,3′-R),  (3-R,3′-S)  and  (3-S,3′-S).  Disodium 
disuccinate  astaxanthin  (DDA)  is  a  synthetic  astaxanthin  containing  a  mixture  of  all  three 
stereoisomers, in the proportions 1:2:1. DDA was manufactured by Cardax Pharmaceuticals and used 
in animal studies investigating the myocardial ischemia-reperfusion injury models [34–36,52–54]. This 
form of astaxanthin was touted to have better aqueous solubility, unlike other carotenoids, and this 
enabled both oral and intravenous administration. DDA is no longer available but the same company 
now produces a second synthetic astaxanthin compound; Heptax/XanCor, CDX-085. The company 
claims that it is developed for thrombotic protection, triglyceride reduction, metabolic syndrome, and 
inflammatory  liver  disease.  In  addition,  it  has  increased  water  dispersibility  and  enhanced 
bioavailability compared to natural astaxanthin and DDA. The synthetic forms are metabolized via 
hydrolysis in the intestine yielding free astaxanthin for intestinal absorption. CDX-085 has been used 
in one study, discussed below [55].  
It is not yet clear which form of astaxanthin should be administered in clinical studies, the natural 
form from the marine environment or a synthetic form. As the proportions of stereoisomers, vary 
between these different forms of astaxanthin they may not be therapeutically equivalent [56]. Thus 
synthetic astaxanthin could result in different outcomes when assessed clinically [57].  
6. Astaxanthin-Experimental Studies 
Experimental studies undertaken with astaxanthin specifically relevant to the cardiovascular system 
are summarised in Table 1. Astaxanthin attenuates mediators of oxidative stress and inflammation and 
has shown beneficial effects in non-cardiovascular models of disease [58–69]. In addition, astaxanthin 
has decreased markers of lipid peroxidation [70], inflammation [61,62,67,68] and thrombosis [55]. 
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Table 1. Animal studies investigating the cardiovascular effects of astaxanthin. 
Study  Model  Dosage 
Duration/timing of 
supplementation 
Effects of astaxanthin 
Lauver et al.  
2008 [34] 
Dog with occlusive 
carotid artery thrombus 
DDA 10, 30, or 
50 mg/kg/body weight IV 
30 min after 
occlusion 
 
- Reduced incidence of secondary thrombosis 
Aoi et al.  
2003 [63] 
C57BL/6 mice  Diet supplemented with 
astaxanthin 0.02% 
weight/weight and food 
intake recorded 
3 weeks  - Attenuation of exercise increased 4-hydroxy-2-
nonenal-modified protein and 8-hydroxy-2′-
deoxyguanosine in cardiac and gastrocnemius muscle 
- Attenuation of exercise increases in creatine kinase 
and myeloperoxidase activity in cardiac and 
gastrocnemius muscle 
- Astaxanthin accumulated in cardiac and gastrocnemius 
muscle 
 
Gross and 
Lockwood  
2004 [35] 
Myocardial infarct 
model Sprague-Dawley 
rats 
DDA 25/50/75 mg/kg 
body weight 
intravenously daily 
4 days prior to 
myocardial 
infarction 
 
- Myocardial infarct size significantly reduced  
Hussein et al.  
2005 [71] 
Stroke prone 
Spontaneously 
hypertensive rats 
 
Astaxanthin 50 mg/kg 
body weight/day 
5 weeks  - Significant blood pressure reduction 
- Delayed incidence of stroke 
Lauver et al.  
2005 [52] 
Rabbit model of 
myocardial 
ischemia/reperfusion 
DDA 50 mg/kg 
body weight/day 
intravenously 
 
5 days  - Significant reduction in complement activation 
- Significant reduction in myocardial infarct size 
Gross et al.  
2005 [54] 
Canine model of 
myocardial 
ischemia/reperfusion 
DDA 50 mg/kg 
body weight/day 
intravenously 
2 h or daily for  
four days  
- Significant reduction in myocardial infarct size 
- Two of three dogs treated for four days had 100% 
cardiac protection  Mar. Drugs 2011, 9  
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Table 1. Cont. 
Gross et al.  
2006 [36] 
Sprague-Dawley rats 
Left anterior descending 
coronary artery 
occlusion/reperfusion 
 
DDA 125 or 500 mg/kg 
body weight/day orally 
7 days  - Astaxanthin loading of myocardium indicating good 
bioavailability 
- Trends in lowering of lipid peroxidation products 
- Significant reduction in myocardial infarct size 
Hussein et al.  
2006 [72] 
Spontaneously 
hypertensive rats 
Astaxanthin 5% in olive 
oil (5 mg/kg/day orally)  
7 days  - Significant reduction in nitric oxide end products 
- Significant reduction in elastin bands in aorta  
- Significant reduction in wall/lumen arterial ratio in coronary 
arteries 
 
Aoi et al.  
2008 [73] 
ICR mice  Astaxanthin 0.02% w/w  4 weeks  Astaxanthin increased fat utilization during exercise and prolonged 
exercise 
Astaxanthin prevented increase in hexanoyl-lysine modification of 
CPT I with exercise 
 
Nakao et al.  
2010 [74] 
BALC/c mice  Astaxanthin 0, 0.02, 
0.08% orally/day 
8 weeks  - No change in blood glutathione concentration 
- No change in lymphocyte mitochondrial membrane potential 
- Higher myocardial mitochondrial membrane potential and 
contractility index 
 
Khan et al.  
2010 [55]  
C57BL/6 mice 
 
 
Human umbilical vein 
endothelial cells and 
platelets from  
Wistar-Kyoto rats 
CDX-085 500 mg/kg 
body weight/day 
14 days  - CDX-085 administered orally to C57BL/6 mice was associated 
with presence of free astaxanthin in the plasma, heart, liver and 
platelets 
- Mice fed astaxanthin had significantly increased basal arterial 
blood flow and delay in occlusive thrombosis after endothelial 
injury 
- Human umbilical vein endothelial cells and platelets from 
Wistar-Kyoto rats treated with free astaxanthin has significantly 
increased release of nitric oxide and decreased peroxynitrite levels Mar. Drugs 2011, 9  
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6.1. Cardiovascular Studies 
A  series  of  experiments  have  been  conducted  to  assess  the  efficacy  of  DDA  in  protecting  the 
myocardium using the myocardial ischemia-reperfusion model in rats, rabbits and dogs [35,36,53,54]. 
Prior treatment for four-days with intravenous DDA using doses of 25, 50 and 75 mg/kg body weight 
in  Sprague-Dawley  rats  significantly  reduced  myocardial  infarct  size  [35].  The  degree  of  cardiac 
protection correlated with the dose of DDA administered. In a study in rabbits using a myocardial 
ischaemia-reperfusion model prior intravenous treatment with 50 mg/kg/day of DDA for four days 
resulted  in  a  significant  decrease  in  the  size of  the  myocardial infarction and  an  improvement  in 
myocardial  salvage  [52].  Animals  treated  with  DDA  had  an  attenuation  of  inflammation  and 
complement activation suggesting there was a reduction in tissue inflammation [52]. In another study 
using a dog model intravenous DDA was administered daily for four-days prior to occlusion of the left 
anterior descending coronary artery or two hours prior to coronary artery occlusion [54]. After an hour 
of coronary occlusion and three hours of reperfusion there was a significant reduction in myocardial 
infarct size in the dogs treated with DDA. In the four-day treatment group, two out of three dogs had 
complete cardiac protection [54]. In a rat study, the effects of seven days of pre-treatment with oral 
DDA, 125 and 500 mg/kg/day on the concentrations of free astaxanthin in myocardial tissue [36]. The 
astaxanthin concentration in the myocardium was 400 nM after oral DDA at a dose of 125 mg/kg/day 
for seven-days and it was 1634 nM after 500 mg/kg/day. There was also a reduction of multiple lipid 
peroxidation products. The doses of DDA used in these experiments were quite high and at this stage it 
is not known whether such doses would be safe to use in humans.  
The effects of astaxanthin on blood pressure (BP) were assessed in spontaneously hypertensive 
rats (SHR). There was a significant reduction in BP after 14-days of oral astaxanthin administration 
whereas this did not occur in normotensive Wistar Kyoto rats [71]. Astaxanthin administered orally for 
five-weeks in stroke prone SHR also resulted in a significant BP reduction [71]. Oral astaxanthin also 
enhanced nitric oxide induced vascular relaxation in the rat aortas [71] In experiments in SHR, oral 
astaxanthin significantly decreased nitric oxide end products indicating that it may be exerting its BP 
effects via this pathway [72]. Studies using the SHR aorta and coronary arteries demonstrated that 
astaxanthin  reduced  the  wall/lumen  ratio  in  coronary  arteries  and  decreased  elastin  bands  in  the  
aorta [72]. This suggests that astaxanthin may beneficially mediate atherosclerotic CVD processes.  
Recently, a series of two experiments were reported in the one article, one using the synthetic 
astaxanthin (CDX-085) and the other using free astaxanthin [55]. CDX-085 administered orally to 
C57BL/6 mice resulted in the presence of free astaxanthin in the plasma, heart, liver and platelets. 
Mice that were fed astaxanthin had significantly increased basal arterial blood flow and a delay in 
occlusive  thrombosis  after  endothelial  injury.  Also,  in  an  in  vitro  study,  human  umbilical  vein 
endothelial cells and platelets isolated from Wistar-Kyoto rats that were treated with free astaxanthin 
has significantly increased nitric oxide release and a decrease in peroxynitrite levels [55]. The authors 
concluded the results support the potential of astaxanthin as a potential therapy to prevent thrombosis 
associated with cardiovascular disease. 
Astaxanthin administered to C57BL/6 mice resulted in a reduction in exercise-induced increases in 
the  oxidative  stress  biomarkers  8-hydroxy-2′-deoxyguanosine  and  4-hydroxy-2-nonenal-modified 
protein in both cardiac and gastrocnemius muscle [63]. Increases in myeloperoxidase and creatinine Mar. Drugs 2011, 9  
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kinase  activity  in  cardiac  and  gastrocnemius  muscle  were  also  reduced  by  astaxanthin.  After  
three-weeks  of  astaxanthin  supplementation  there  was  evidence  of  accumulation  of  astaxanthin  in 
gastrocnemius and cardiac muscle. Astaxanthin given to female BALB/c mice for eight-weeks resulted 
in a dose dependent increase in plasma astaxanthin but no significant changes in blood glutathione or 
change in lymphocyte mitochondrial membrane potential and cardiac contractility index measured on 
echocardiography.  The  mice  that  were  fed  0.08%  astaxanthin  in  the  diet  had  higher  cardiac 
mitochondrial membrane potential and contractility index compared with control animals [74]. This 
suggests dietary astaxanthin provides cardiac protection. Astaxanthin administered for four weeks to 
eight week old ICR mice resulted in increased exercised induced fat utilization and prevention of 
increased hexanoyl-lysine modification of carnitine palmitoyltransferase I (CTP I) [73]. In a canine 
carotid artery thrombosis model, administration of DDA resulted in a dose-dependent reduction in 
carotid artery re-thrombosis and a reduction of re-thrombosis after thrombolysis but there was no 
effect on hemostasis [34].  
6.2. Diabetes Studies 
Diabetes mellitus and its associated nephropathy is a common cause of chronic kidney disease and 
is complicated by accelerated atherosclerotic cardiovascular disease [75]. In studies involving diabetic 
db/db mice, supplementation with astaxanthin produced a reduction in the levels of blood glucose [60]. 
In the kidney there was significantly decreased relative mesangial area in the animals supplemented 
with  astaxanthin.  Also  proteinuria  and  urinary  excretion  of  8-OHdG  were  attenuated.  Mice 
supplemented  with  astaxanthin  had  less  glomerular  8-OHdG  immunoreactive  cells  [60]. 
Hyperglycemia induced reactive oxygen species production, activation of transcription factors, and 
cytokine expression and production by normal human mesangial cells was suppressed significantly by 
astaxanthin [66].  
7. Astaxanthin Studies in Humans  
Although no cardiovascular outcomes studies using astaxanthin have been reported in humans there 
have been clinical studies that have investigated the effects of astaxanthin in human health and other 
diseases (Table 2). The majority of these have been conducted in healthy participants who volunteered 
to assess astaxanthin dose, bioavailability, safety and oxidative stress, which are all potentially relevant 
to the cardiovascular system. Studies have also been conducted in other medical conditions such as 
reflux oesophagitis, where measurements of oxidative stress and/or inflammation have been included.  
7.1. Dosing  
Human  clinical  studies  have  used  oral  astaxanthin  in  a  dose  that  ranges  from  4  mg  up  to 
100 mg/day, given from a one off dose up to durations of one-year (Table 2).  
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Table 2. Clinical studies investigating the safety, bioavailability and effects of astaxanthin on oxidative stress. 
Study 
Study population 
(n = subject numbers) 
Dosage  Study design 
Duration of 
supplementation 
Effects of astaxanthin 
Iwamoto et al. 
2000 [70] 
Volunteers (n = 24)  Different 
doses: 1.8, 
3.6, 14.4, 
21.6 mg/day 
 
Open labelled  2 weeks  - Reduction of LDL oxidation 
Osterlie et al.  
2000 [76] 
Middle aged male 
volunteers (n = 3) 
100 mg  Open labelled  Single dose  - Astaxanthin taken up by VLDL chylomicrons 
 
Mercke Odeberg et al. 
2003 [77] 
Healthy male 
volunteers (n = 32) 
40 mg  
 
Open labelled 
parallel 
Single dose  - Enhanced bioavailability with lipid based 
formulation 
 
Spiller et al.  
2003 [78] 
Healthy adults (n = 35)  6 mg/day  
(3 ×  2 mg 
tablets/day) 
 
Randomised, 
double blind, 
placebo 
controlled 
 
8 weeks  - Demonstrated safety assessed by measures of 
blood pressure and biochemistry  
 
Coral-Hinostroza et al. 
2005 [79] 
Healthy adult males 
(n = 3) 
10 mg and 
100 mg 
Open labelled  Single dose or  
4 weeks 
- Cmax 0.28 mg/L at 11.5 h at high dose and 
0.08 mg/L at low dose 
- Elimination half life 52 ±  40 h 
- z-isomer selectively absorbed 
 
Karppi et al.  
2007 [80] 
Healthy non-smoking 
Finnish males (n = 40) 
8 mg/day  Randomised, 
double blind, 
placebo 
controlled 
12 weeks  - Intestinal absorption adequate with capsules 
- Reduced levels of plasma 12 and 15 hydroxy 
fatty acids  
- Decreased oxidation of fatty acids 
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Table 2. Cont. 
Parisi et al.  
2008 [81] 
Non-advanced age 
related macular 
degeneration 
(n = 27) 
4 mg/day  Randomised 
controlled trial 
open labelled no 
placebo 
12 months  - Improved central retinal dysfunction in age 
related macular degeneration when administered 
with other antioxidants 
Miyawaki et al. 
2008 [82] 
Healthy males 
(n = 20) 
6 mg/day  Single blind, 
placebo 
controlled 
10 days  - Decreased whole blood transit time (improved 
blood rheology) 
Rufer et al.  
2008 [83] 
Healthy males 
(n = 28) 
5 g/g salmon 
flesh (wild vs. 
aquacultured) 
Randomised, 
double blind, 
placebo 
controlled 
4 weeks  - Bioavailability initially better with ingestion of 
aquacultured salmon but equivalent at day 28. 
Isomer (3S, 3′S) greater in plasma compared with 
isomer proportion in salmon flesh 
Park et al.  
2010 [84] 
Healthy females 
(n = 14) 
0, 2, 8 mg/day 
 
Randomised, 
double blind, 
placebo 
controlled 
8 weeks  - Decreased plasma 8-hydroxy-2′-deoxyguanosine 
after week four in those taking astaxanthin. 
- Lower CRP after week four in those taking 
2 mg/day astaxanthin  
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7.2. Bioavailability  
Astaxanthin  bioavailability  from  the  marine  environment  was  assessed  in  a randomised  double 
blind trial in 28 volunteers [83]. Participants were given either 250 g of wild salmon or aquaculture 
salmon (5  µ g/g) to eat. Wild salmon ingest astaxanthin naturally from krill whereas aquacultured 
salmon acquire it from fish that are fed astaxanthin that might be derived from a synthetic source. 
Plasma levels of astaxanthin were higher at 3, 6, 10 and 14 days during ingestion of the aquacultured 
compared with the wild salmon. Plasma levels of the (3-S, 3′-S) isomer of astaxanthin appeared at 
higher levels than its proportionate level in the flesh of the salmon. This suggests that isomers of 
astaxanthin might have different bioavailability. The plasma isomers of astaxanthin have also been 
studied after ingestion of single oral dose of 10mg and also 100 mg over four-weeks. Astaxanthin 
plasma elimination half-life was 52 (SD 40) h and there was a non-linear dose response and selective 
absorption of z-isomers [79].  
7.3. Safety  
The  safety  of  astaxanthin  administered  orally  was  assessed  in  a  double-blind,  randomised  
placebo-controlled  trial  undertaken  in  healthy  adults  [78].  Volunteers  took  either  6  mg/day  of 
astaxanthin or placebo for eight-weeks. BP and biochemistry measured after four and eight weeks of 
therapy revealed no significant differences in these parameters between treatment and placebo groups 
and these did not differ from baseline. The authors concluded that healthy adults could safely consume 
6 mg/day of astaxanthin derived from a Haematococcus pluvialis algal extract. Measuring whole blood 
transit time in 20 healthy males was used to assess the effects of astaxanthin on blood rheology in 
humans. Six milligrams of oral astaxanthin per day for ten days improved blood rheology as evidenced 
by  decreased  whole  blood  transit  time  [82].  Escalating  concentrations  of  astaxanthin  were  tested 
in vitro with blood taken from volunteers, 8 of whom were taking asprin and 12 who were not [85]. 
Even supra-therapeutic concentrations of astaxanthin had no adverse effects on indices of platelet, 
coagulation and fibrinolytic function. These results support the safety profile of astaxanthin for future 
clinical trials. No significant side effects have been reported so far in published human studies in 
which astaxanthin was administered to humans. 
7.4. Oxidative Stress and Inflammation  
Oral supplementation with astaxanthin in studies in healthy human volunteers and patients with 
reflux  oesophagitis  demonstrated  a  significant  reduction  in  oxidative  stress,  hyperlipidemia  and 
biomarkers  of  inflammation  [70,80,86].  In  a  study  involving  24  healthy  volunteers  who  ingested 
astaxanthin  in  doses  from  1.8  to  21.6  mg/day  for  two  weeks,  LDL  lag  time,  as  a  measure  of 
susceptibility  of  LDL  to  oxidation,  was  significantly  greater  in  astaxanthin  treated  participants 
indicating inhibition of the oxidation of LDL [70]. Plasma levels of 12- and 15-hydroxy fatty acids 
were significantly reduced in 40 healthy non-smoking Finnish males given astaxanthin [80] suggesting 
astaxanthin decreased the oxidation of fatty acids [80]. The effects of dietary astaxanthin in doses of  
0, 2 or 8 mg/day, over 8 weeks, on oxidative stress and inflammation were investigated in a double 
blind study in 14 healthy females [84]. Although these participants did not have oxidative stress or Mar. Drugs 2011, 9  
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inflammation those taking 2 mg/day had lower CRP at week eight. There was also a decrease in DNA 
damage  measured  using  plasma  8-hydroxy-2′-deoxyguanosine  after  week  four  in  those  taking 
astaxanthin. Astaxanthin therefore appears safe, bioavailable when given orally and is suitable for 
further investigation in humans.  
8. Clinical Trial Using Astaxanthin  
A  double-blind  randomised  placebo-controlled  clinical  trial  (Xanthin  study)  is  currently  being 
conducted to assess the effects of astaxanthin 8mg orally day on oxidative stress, inflammation and 
vascular  function  in  patients  that  have  received  a  kidney  transplant  [87].  Patients  in  the  study 
undertake measurements of surrogate markers of cardiovascular disease including aortic pulse wave 
velocity, augmentation index, brachial forearm reactivity and carotid artery intima-media thickness. 
Depending on the results from this pilot study a large randomised controlled trial assessing major 
cardiovascular outcomes such as myocardial infarction and death may be warranted.  
9. Conclusions  
Experimental evidence suggests astaxanthin may have protective effects on cardiovascular disease 
when administered prior to an induced ischemia-reperfusion event. In addition, there is evidence that 
astaxanthin may decrease oxidative stress and inflammation which are known accompaniments of 
cardiovascular disease. At this stage we do not know whether astaxanthin has any therapeutic value in 
human  cardiovascular  disease  either  in  a  preventative  capacity  or  when  administered  after  a 
cardiovascular insult. It has been proposed that astaxanthin may provide cardiovascular protection 
through reducing oxidative stress, which is one of the non-traditional risk factors for the development 
of  atherosclerotic  cardiovascular  disease.  The  role  of  oxidative  stress  in  cardiovascular  disease  is 
supported by evidence from observational studies that have found associations between antioxidant 
intake, oxidative stress and cardiovascular outcomes. Despite this, clinical intervention studies using 
antioxidants including vitamin E, -carotene and vitamin C, have not proved successful [22,23]. These 
intervention studies may have failed because of flawed design where patients were not included based 
on the presence of oxidative stress. Hence, many participants may not have been in a state of oxidative 
stress and able to benefit from antioxidant therapy. Also, in those participants where oxidative stress 
may have existed there was no way of assessing whether the therapy adequately corrected this. Thus, 
the  antioxidants  used  such  as  vitamin  E,  -carotene  and  vitamin  C  may  not  have  been  effective 
because  insufficient  doses  were  used  or  an  inadequate  length  of  therapy  followed  to  correct  the 
oxidative stress. Some antioxidants such as -carotene may be pro-oxidant at higher doses, which 
could have confounded study results.  
Astaxanthin is a potent antioxidant and based on its physicochemical properties and the results of 
preliminary  experimental  studies  in  ischaemia-reperfusion  models  of  cardiovascular  disease,  it 
warrants consideration for testing in human clinical trials. There have been no safety concerns noted so 
far in human clinical studies where astaxanthin has been administered. As astaxanthin is a potent 
antioxidant and is associated with membrane preservation, it may protect against oxidative stress and 
inflammation and provide cardiovascular benefits.  
   Mar. Drugs 2011, 9  
 
 
459 
Acknowledgements 
Cyanotech the manufacturer of BioAstin, a proprietary brand of astaxanthin, is providing financial 
support and astaxanthin capsules and placebo for a clinical trial being conducted by the authors. The 
sponsor has no role in the study itself.  
References  
1.  Dzau, V.J.; Antman, E.M.; Black, H.R.; Hayes, D.L.; Manson, J.E.; Plutzky, J.; Popma, J.J.; 
Stevenson, W. The cardiovascular disease continuum validated: Clinical evidence of improved 
patient outcomes. Part II: Clinical trial evidence (acute coronary syndromes through renal disease) 
and future directions. Circulation 2006, 114, 2871–2891. 
2.  Ellingsen, I.; Seljeflot, I.; Arnesen, H.; Tonstad, S. Vitamin C consumption is associated with less 
progression in carotid intima media thickness in elderly men: A 3-year intervention study. Nutr. 
Metab. Cardiovasc. Dis. 2009, 19, 8–14. 
3.  Carty, J.L.; Bevan, R.; Waller, H.; Mistry, N.; Cooke, M.; Lunec, J.; Griffiths, H.R. The effects of 
vitamin C supplementation on protein oxidation in healthy volunteers. Biochem. Biophys. Res. 
Commun. 2000, 273, 729–735. 
4.  Carpenter, K.L.; Kirkpatrick, P.J.; Weissberg, P.L.; Challis, I.R.; Dennis, I.F.; Freeman, M.A.; 
Mitchinson, M.J. Oral alpha-tocopherol supplementation inhibits lipid oxidation in established 
human atherosclerotic lesions. Free Radic. Res. 2003, 37, 1235–1244. 
5.  Stampfer,  M.J.;  Hennekens,  C.H.;  Manson,  J.E.;  Colditz,  G.A.;  Rosner,  B.;  Willett,  W.C. 
Vitamin E consumption and the risk of coronary disease in women. N. Engl. J. Med. 1993, 328, 
1444–1449. 
6.  Rimm,  E.B.;  Stampfer,  M.J.;  Ascherio,  A.;  Giovannucci,  E.;  Colditz,  G.A.;  Willett,  W.C. 
Vitamin E consumption and the risk of coronary heart disease in men. N. Engl. J. Med. 1993, 328, 
1450–1456. 
7.  Gey, K.F.; Puska, P. Plasma vitamins E and A inversely correlated to mortality from ischemic 
heart disease in cross-cultural epidemiology. Ann. N. Y. Acad. Sci. 1989, 570, 268–282. 
8.  Willcox, B.J.; Curb, J.D.; Rodriguez, B.L. Antioxidants in cardiovascular health and disease: Key 
lessons from epidemiologic studies. Am. J. Cardiol. 2008, 101, 75D–86D. 
9.  Frei,  B.  Cardiovascular  disease  and  nutrient  antioxidants:  Role  of  low-density  lipoprotein 
oxidation. Crit. Rev. Food Sci. Nutr. 1995, 35, 83–98. 
10.  Steinberg,  D.  Antioxidants  in  the  prevention  of  human  atherosclerosis.  Summary  of  the 
proceedings of a National Heart, Lung, and Blood Institute Workshop: September 5–6, 1991, 
Bethesda, Maryland. Circulation 1992, 85, 2337–2344. 
11.  Helmersson,  J.;  Arnlov,  J.;  Larsson,  A.;  Basu,  S.  Low  dietary  intake  of  beta-carotene,  
alpha-tocopherol and ascorbic acid is associated with increased inflammatory and oxidative stress 
status in a Swedish cohort. Br. J. Nutr. 2009, 101, 1775–1782. 
12.  Osganian,  S.K.;  Stampfer,  M.J.;  Rimm,  E.;  Spiegelman,  D.;  Manson,  J.E.;  Willett,  W.C. 
Dietary carotenoids and risk of coronary artery disease in women. Am. J. Clin. Nutr. 2003, 77, 
1390–1399. Mar. Drugs 2011, 9  
 
 
460 
13.  Ford,  E.S.; Giles,  W.H.  Serum  vitamins,  carotenoids,  and angina  pectoris:  Findings  from  the 
National Health and Nutrition Examination Survey III. Ann. Epidemiol. 2000, 10, 106–116. 
14.  Klipstein-Grobusch,  K.;  Geleijnse,  J.M.;  den  Breeijen,  J.H.;  Boeing,  H.;  Hofman,  A.;  
Grobbee,  D.E.;  Witteman,  J.C.  Dietary  antioxidants  and  risk  of  myocardial  infarction  in  the 
elderly: The Rotterdam Study. Am. J. Clin. Nutr. 1999, 69, 261–266. 
15.  Gaziano,  J.M.;  Manson,  J.E.;  Branch,  L.G.;  Colditz,  G.A.;  Willett,  W.C.;  Buring,  J.E.  
A  prospective  study  of  consumption  of  carotenoids  in  fruits  and  vegetables  and  decreased 
cardiovascular mortality in the elderly. Ann. Epidemiol. 1995, 5, 255–260. 
16.  Morris,  D.L.;  Kritchevsky,  S.B.;  Davis,  C.E.  Serum  carotenoids  and  coronary  heart  disease. 
The Lipid  Research  Clinics  Coronary  Primary  Prevention  Trial  and  Follow-up  Study.  JAMA 
1994, 272, 1439–1441. 
17.  Knekt, P.; Reunanen, A.; Jarvinen, R.; Seppanen, R.; Heliovaara, M.; Aromaa, A. Antioxidant 
vitamin intake and coronary mortality in a longitudinal population study. Am. J. Epidemiol. 1994, 
139, 1180–1189. 
18.  Stephens,  N.G.;  Parsons,  A.;  Schofield,  P.M.;  Kelly,  F.;  Cheeseman,  K.;  Mitchinson,  M.J. 
Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart 
Antioxidant Study (CHAOS). Lancet 1996, 347, 781–786. 
19.  Tepel, M.; van der Giet, M.; Statz, M.; Jankowski, J.; Zidek, W. The antioxidant acetylcysteine 
reduces cardiovascular events in patients with end-stage renal failure: A randomized, controlled 
trial. Circulation 2003, 107, 992–995. 
20.  Boaz, M.; Smetana, S.; Weinstein, T.; Matas, Z.; Gafter, U.; Iaina, A.; Knecht, A.; Weissgarten, Y.; 
Brunner, D.; Fainaru, M.; Green, M.S. Secondary prevention with antioxidants of cardiovascular 
disease in endstage renal disease (SPACE): Randomised placebo-controlled trial. Lancet 2000, 
356, 1213–1218. 
21.  Steinhubl,  S.R.  Why  have  antioxidants  failed  in  clinical  trials?  Am.  J.  Cardiol.  2008,  101,  
14D–19D. 
22.  Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant 
vitamin supplementation in 20,536 high-risk individuals: A randomised placebo-controlled trial. 
Lancet 2002, 360, 23–33. 
23.  Yusuf,  S.;  Dagenais,  G.;  Pogue,  J.;  Bosch,  J.;  Sleight,  P.  Vitamin  E  supplementation  and 
cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study 
Investigators. N. Engl. J. Med. 2000, 342, 154–160. 
24.  Sandmann, G. Carotenoid biosynthesis in microorganisms and plants. Eur. J. Biochem. 1994, 223, 
7–24. 
25.  McNulty,  H.;  Jacob,  R.F.;  Mason,  R.P.  Biologic  activity  of  carotenoids  related  to  distinct 
membrane physicochemical interactions. Am. J. Cardiol. 2008, 101, 20D–29D. 
26.  Jackson,  H.;  Braun,  C.L.;  Ernst,  H.  The  chemistry  of  novel  xanthophyll  carotenoids.  Am.  J. 
Cardiol. 2008, 101, 50D–57D. 
27.  McNulty,  H.P.;  Byun,  J.;  Lockwood,  S.F.;  Jacob,  R.F.;  Mason,  R.P.  Differential  effects  of 
carotenoids  on  lipid  peroxidation  due  to  membrane  interactions:  X-ray  diffraction  analysis. 
Biochim. Biophys. Acta 2007, 1768, 167–174. Mar. Drugs 2011, 9  
 
 
461 
28.  Brown, B.G.; Zhao, X.Q.; Chait, A.; Fisher, L.D.; Cheung, M.C.; Morse, J.S.; Dowdy, A.A.; 
Marino,  E.K.;  Bolson,  E.L.;  Alaupovic,  P.;  Frohlich,  J.;  Albers,  J.J.  Simvastatin  and  niacin, 
antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 
2001, 345, 1583–1592. 
29.  The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E 
and beta carotene on the incidence of lung cancer and other cancers in male smokers. N. Engl. J. 
Med. 1994, 330, 1029–1035. 
30.  Omenn,  G.S.;  Goodman,  G.E.;  Thornquist,  M.D.;  Balmes,  J.;  Cullen,  M.R.;  Glass,  A.;  
Keogh, J.P.; Meyskens, F.L.; Valanis, B.; Williams, J.H.; Barnhart, S.; Hammar, S. Effects of a 
combination  of  beta  carotene  and  vitamin  A  on  lung  cancer  and  cardiovascular  disease.  
N. Engl. J. Med. 1996, 334, 1150–1155. 
31.  Lee,  I.M.;  Cook,  N.R.;  Manson,  J.E.;  Buring,  J.E.;  Hennekens,  C.H.  Beta-carotene 
supplementation and incidence of cancer and cardiovascular disease: The Women’s Health Study. 
J. Natl. Cancer Inst. 1999, 91, 2102–2106. 
32.  Hennekens,  C.H.;  Buring,  J.E.;  Manson,  J.E.;  Stampfer,  M.;  Rosner,  B.;  Cook,  N.R.;  
Belanger, C.; LaMotte, F.; Gaziano, J.M.; Ridker, P.M.; Willett, W.; Peto, R. Lack of effect of 
long-term  supplementation  with  beta  carotene  on  the  incidence  of  malignant  neoplasms  and 
cardiovascular disease. N. Engl. J. Med. 1996, 334, 1145–1149. 
33.  Burton, G.W.; Ingold, K.U. beta-Carotene: An unusual type of lipid antioxidant. Science 1984, 
224, 569–573. 
34.  Lauver, D.A.; Driscoll, E.M.; Lucchesi, B.R. Disodium disuccinate astaxanthin prevents carotid 
artery rethrombosis and ex vivo platelet activation. Pharmacology 2008, 82, 67–73. 
35.  Gross, G.J.; Lockwood, S.F. Cardioprotection and myocardial salvage by a disodium disuccinate 
astaxanthin derivative (Cardax). Life Sci. 2004, 75, 215–224. 
36.  Gross, G.J.; Hazen, S.L.; Lockwood, S.F. Seven day oral supplementation with Cardax (disodium 
disuccinate astaxanthin) provides significant cardioprotection and reduces oxidative stress in rats. 
Mol. Cell. Biochem. 2006, 283, 23–30. 
37.  Wertz, K.; Hunziker, P.B.; Seifert, N.; Riss, G.; Neeb, M.; Steiner, G.; Hunziker, W.; Goralczyk, R. 
beta-Carotene interferes with ultraviolet light A-induced gene expression by multiple pathways.  
J. Invest. Dermatol. 2005, 124, 428–434. 
38.  Camera,  E.;  Mastrofrancesco,  A.;  Fabbri,  C.;  Daubrawa,  F.;  Picardo,  M.;  Sies,  H.;  Stahl,  W. 
Astaxanthin, canthaxanthin and beta-carotene differently affect UVA-induced oxidative damage and 
expression of oxidative stress-responsive enzymes. Exp. Dermatol. 2009, 18, 222–231. 
39.  Camara, B.; Bouvier, F. Oxidative remodeling of plastid carotenoids. Arch. Biochem. Biophys. 
2004, 430, 16–21. 
40.  Sharoni, Y.; Agbaria, R.; Amir, H.; Ben-Dor, A.; Bobilev, I.; Doubi, N.; Giat, Y.; Hirsh, K.; 
Izumchenko, G.; Khanin, M.; Kirilov, E.; Krimer, R.; Nahum, A.; Steiner, M.; Walfisch, Y.; 
Walfisch,  S.;  Zango,  G.;  Danilenko,  M.;  Levy,  J.  Modulation  of  transcriptional  activity  by 
antioxidant carotenoids. Mol. Asp. Med. 2003, 24, 371–384. 
41.  Guerin, M.; Huntley, M.E.; Olaizola, M. Haematococcus astaxanthin: Applications for human 
health and nutrition. Trends Biotechnol. 2003, 21, 210–216. Mar. Drugs 2011, 9  
 
 
462 
42.  Hussein, G.; Sankawa, U.; Goto, H.; Matsumoto, K.; Watanabe, H. Astaxanthin, a carotenoid with 
potential in human health and nutrition. J. Nat. Prod. 2006, 69, 443–449. 
43.  Schweigert,  F.  Metabolism  of  Carotenoids  in  Mammals;  Birkhauser  Verlag:  Basel,  
Switzerland, 1998. 
44.  Jyonouchi, H.; Sun, S.; Tomita, Y.; Gross, M.D. Astaxanthin, a carotenoid without vitamin A 
activity, augments antibody responses in cultures including T-helper cell clones and suboptimal 
doses of antigen. J. Nutr. 1995, 125, 2483–2492. 
45.  Shimidzu, N. Carotenoids as singlet oxygen quenchers in marine organisms. Fish. Sci. 1996, 62, 
134–137. 
46.  Miki, W. Biological functions and activities of animal carotenoids. Pure Appl. Chem. 1991, 63, 
141–146. 
47.  Krinsky, N.I. Antioxidant functions of carotenoids. Free Radic. Biol. Med. 1989, 7, 617–635. 
48.  Beutner, S.; Bloedorn, B.; Frixel, S.; Blanco, I.H.; Hoffman, T.; Martin, H.D.; Mayer, B.; Noach, P.; 
Rack, C.; Schmidt, M.; et al. Quantitative assessment of antioxidant properties of natural colorants 
and phytochemicals; carotenoids. flavonoids, phenols and indigoids: The role of β-carotene in 
antioxidant functions. J. Sci. Food Agric. 2001, 81, 559–568. 
49.  Pashkow,  F.J.; Watumull,  D.G.; Campbell,  C.L. Astaxanthin:  A novel potential treatment  for 
oxidative stress and inflammation in cardiovascular disease. Am. J. Cardiol. 2008, 101, 58D–68D. 
50.  Kobayashi, M.; Kakizono, T.; Nishio, N.; Nagai, S.; Kurimura, Y.; Tsuji, Y. Antioxidant role of 
astaxanthin in the green alga Haematococcus pluvialis. Appl. Microbiol. Biotechnol. 1997, 48, 
351–356. 
51.  Ernst,  H.  Recent  advances  in  industrial  carotenoid  synthesis.  Pure  Appl.  Chem.  2002,  74,  
2213–2226. 
52.  Lauver,  D.A.;  Lockwood,  S.F.;  Lucchesi,  B.R.  Disodium  Disuccinate  Astaxanthin  (Cardax) 
attenuates complement activation and reduces myocardial injury following ischemia/reperfusion. 
J. Pharmacol. Exp. Ther. 2005, 314, 686–692. 
53.  Lockwood,  S.F.;  Gross,  G.J.  Disodium  disuccinate  astaxanthin  (Cardax):  Antioxidant  and 
antiinflammatory cardioprotection. Cardiovasc. Drug Rev. 2005, 23, 199–216. 
54.  Gross,  G.J.;  Lockwood,  S.F.  Acute  and  chronic  administration  of  disodium  disuccinate 
astaxanthin (Cardax) produces marked cardioprotection in dog hearts. Mol. Cell. Biochem. 2005, 
272, 221–227. 
55.  Khan, S.K.; Malinski, T.; Mason, R.P.; Kubant, R.; Jacob, R.F.; Fujioka, K.; Denstaedt, S.J.; 
King,  T.J.;  Jackson,  H.L.;  Hieber,  A.D.;  Lockwood,  S.F.;  Goodin,  T.H.;  Pashkow,  F.J.;  
Bodary, P.F. Novel astaxanthin prodrug (CDX-085) attenuates thrombosis in a mouse model. 
Thromb. Res. 2010, 126, 299–305. 
56.  Shargel, L.; Yu, A. Applied Biopharmaceutics and Pharmacokinetics; Appleton-Lange: Stamford, 
CT, USA, 1999. 
57.  Rishton, G.M. Natural products as a robust source of new drugs and drug leads: Past successes 
and present day issues. Am. J. Cardiol. 2008, 101, 43D–49D. 
58.  Kang, J.O.; Kim, S.J.; Kim, H. Effect of astaxanthin on the hepatotoxicity, lipid peroxidation and 
antioxidative enzymes in the liver of CCl4-treated rats. Methods Find. Exp. Clin. Pharmacol. 
2001, 23, 79–84. Mar. Drugs 2011, 9  
 
 
463 
59.  Kamath, B.S.; Srikanta, B.M.; Dharmesh, S.M.; Sarada, R.; Ravishankar, G.A. Ulcer preventive 
and antioxidative properties of astaxanthin from Haematococcus pluvialis. Eur. J. Pharmacol. 
2008, 590, 387–395. 
60.  Naito,  Y.;  Uchiyama,  K.;  Aoi,  W.;  Hasegawa,  G.;  Nakamura,  N.;  Yoshida,  N.;  Maoka,  T.; 
Takahashi, J.; Yoshikawa, T. Prevention of diabetic nephropathy by treatment with astaxanthin in 
diabetic db/db mice. Biofactors 2004, 20, 49–59. 
61.  Ohgami, K.; Shiratori, K.; Kotake, S.; Nishida, T.; Mizuki, N.; Yazawa, K.; Ohno, S. Effects of 
astaxanthin on lipopolysaccharide-induced inflammation in vitro and in vivo. Invest. Ophthalmol. 
Vis. Sci. 2003, 44, 2694–2701. 
62.  Lee, S.J.; Bai, S.K.; Lee, K.S.; Namkoong, S.; Na, H.J.; Ha, K.S.; Han, J.A.; Yim, S.V.; Chang, K.; 
Kwon, Y.G.; Lee, S.K.; Kim, Y.M. Astaxanthin inhibits nitric oxide production and inflammatory 
gene expression by suppressing I(kappa)B kinase-dependent NF-kappaB activation. Mol. Cells 
2003, 16, 97–105. 
63.  Aoi, W.; Naito, Y.; Sakuma, K.; Kuchide, M.; Tokuda, H.; Maoka, T.; Toyokuni, S.; Oka, S.; 
Yasuhara, M.; Yoshikawa, T. Astaxanthin limits exercise-induced skeletal and cardiac muscle 
damage in mice. Antioxid. Redox Signal. 2003, 5, 139–144. 
64.  Uchiyama, K.; Naito, Y.; Hasegawa, G.; Nakamura, N.; Takahashi, J.; Yoshikawa, T. Astaxanthin 
protects beta-cells against glucose toxicity in diabetic db/db mice. Redox Rep. 2002, 7, 290–293. 
65.  Nakajima, Y.; Inokuchi, Y.; Shimazawa, M.; Otsubo, K.; Ishibashi, T.; Hara, H. Astaxanthin, a 
dietary  carotenoid,  protects retinal cells against oxidative stress  in  vitro and in  mice  in  vivo.  
J. Pharm. Pharmacol. 2008, 60, 1365–1374. 
66.  Manabe, E.; Handa, O.; Naito, Y.; Mizushima, K.; Akagiri, S.; Adachi, S.; Takagi, T.; Kokura, S.; 
Maoka,  T.;  Yoshikawa,  T.  Astaxanthin  protects  mesangial  cells  from  hyperglycemia-induced 
oxidative signaling. J. Cell. Biochem. 2008, 103, 1925–1937. 
67.  Nakano, M.; Onodera, A.; Saito, E.; Tanabe, M.; Yajima, K.; Takahashi, J.; Nguyen, V.C. Effect 
of astaxanthin in combination with alpha-tocopherol or ascorbic acid against oxidative damage in 
diabetic ODS rats. J. Nutr. Sci. Vitaminol. (Tokyo) 2008, 54, 329–334. 
68.  Choi, S.K.; Park, Y.S.; Choi, D.K.; Chang, H.I. Effects of astaxanthin on the production of NO 
and the expression of COX-2 and iNOS in LPS-stimulated BV2 microglial cells. J. Microbiol. 
Biotechnol. 2008, 18, 1990–1996. 
69.  Liu, X.; Shibata, T.; Hisaka, S.; Osawa, T. Astaxanthin inhibits reactive oxygen species-mediated 
cellular toxicity in dopaminergic SH-SY5Y cells via mitochondria-targeted protective mechanism. 
Brain Res. 2009, 1254, 18–27. 
70.  Iwamoto, T.; Hosoda, K.; Hirano, R.; Kurata, H.; Matsumoto, A.; Miki, W.; Kamiyama, M.; 
Itakura,  H.;  Yamamoto,  S.;  Kondo,  K.  Inhibition  of  low-density  lipoprotein  oxidation  by 
astaxanthin. J. Atheroscler. Thromb. 2000, 7, 216–222. 
71.  Hussein,  G.;  Nakamura,  M.;  Zhao,  Q.;  Iguchi,  T.;  Goto,  H.;  Sankawa,  U.;  Watanabe,  H. 
Antihypertensive  and  neuroprotective  effects  of  astaxanthin  in  experimental  animals.  
Biol. Pharm. Bull. 2005, 28, 47–52. 
72.  Hussein, G.; Goto, H.; Oda, S.; Sankawa, U.; Matsumoto, K.; Watanabe, H. Antihypertensive 
potential and mechanism of action of astaxanthin: III. Antioxidant and histopathological effects in 
spontaneously hypertensive rats. Biol. Pharm. Bull. 2006, 29, 684–688. Mar. Drugs 2011, 9  
 
 
464 
73.  Aoi,  W.;  Naito,  Y.;  Takanami,  Y.;  Ishii,  T.;  Kawai,  Y.;  Akagiri,  S.;  Kato,  Y.;  Osawa,  T.; 
Yoshikawa, T. Astaxanthin improves muscle lipid metabolism in exercise via inhibitory effect of 
oxidative CPT I modification. Biochem. Biophys. Res. Commun. 2008, 366, 892–897. 
74.  Nakao,  R.;  Nelson,  O.L.;  Park,  J.S.;  Mathison,  B.D.;  Thompson,  P.A.;  Chew,  B.P.  Effect  of 
astaxanthin supplementation on inflammation and cardiac function in BALB/c mice. Anticancer 
Res. 2010, 30, 2721–2725. 
75.  Yamamoto, R.; Kanazawa, A.; Shimizu, T.; Hirose, T.; Tanaka, Y.; Kawamori, R.; Watada, H. 
Association  between  atherosclerosis  and  newly  classified  chronic  kidney  disease  stage  for 
Japanese patients with type 2 diabetes. Diabetes Res. Clin. Pract. 2009, 84, 39–45. 
76.  Osterlie, M.; Bjerkeng, B.; Liaaen-Jensen, S. Plasma appearance and distribution of astaxanthin 
E/Z and R/S isomers in plasma lipoproteins of men after single dose administration of astaxanthin. 
J. Nutr. Biochem. 2000, 11, 482–490. 
77.  Mercke  Odeberg,  J.;  Lignell,  A.;  Pettersson,  A.;  Hoglund,  P.  Oral  bioavailability  of  the 
antioxidant  astaxanthin  in  humans  is  enhanced  by  incorporation  of  lipid  based  formulations.  
Eur. J. Pharm. Sci. 2003, 19, 299–304. 
78.  Spiller, G.A.; Dewell, A. Safety of an astaxanthin-rich Haematococcus pluvialis algal extract:  
A randomized clinical trial. J. Med. Food 2003, 6, 51–56. 
79.  Coral-Hinostroza, G.N.; Ytrestoyl, T.; Ruyter, B.; Bjerkeng, B. Plasma appearance of unesterified 
astaxanthin geometrical E/Z and optical R/S isomers in men given single doses of a mixture of 
optical 3 and 3′R/S isomers of astaxanthin fatty acyl diesters. Comp. Biochem. Physiol. C Toxicol. 
Pharmacol. 2004, 139, 99–110. 
80.  Karppi,  J.;  Rissanen,  T.H.;  Nyyssonen,  K.;  Kaikkonen,  J.;  Olsson,  A.G.;  Voutilainen,  S.;  
Salonen, J.T. Effects of astaxanthin supplementation on lipid peroxidation. Int. J. Vitam. Nutr. 
Res. 2007, 77, 3–11. 
81.  Parisi, V.; Tedeschi, M.; Gallinaro, G.; Varano, M.; Saviano, S.; Piermarocchi, S. Carotenoids and 
antioxidants in age-related maculopathy italian study: Multifocal electroretinogram modifications 
after 1 year. Ophthalmology 2008, 115, 324–333.e2. 
82.  Miyawaki, H.; Takahashi, J.; Tsukahara, H.; Takehara, I. Effects of astaxanthin on human blood 
rheology. J. Clin. Biochem. Nutr. 2008, 43, 69–74. 
83.  Rufer, C.E.; Moeseneder, J.; Briviba, K.; Rechkemmer, G.; Bub, A. Bioavailability of astaxanthin 
stereoisomers from wild (Oncorhynchus spp.) and aquacultured (Salmo salar) salmon in healthy 
men: A randomised, double-blind study. Br. J. Nutr. 2008, 99, 1048–1054. 
84.  Park, J.S.; Chyun, J.H.; Kim, Y.K.; Line, L.L.; Chew, B.P. Astaxanthin decreased oxidative stress 
and inflammation and enhanced immune response in humans. Nutr. Metab. (Lond.) 2010, 7, 18. 
85.  Serebruany, V.; Malinin, A.; Goodin, T.; Pashkow, F. The in vitro effects of Xancor, a synthetic 
astaxanthine derivative, on hemostatic biomarkers in aspirin-naive and aspirin-treated subjects 
with multiple risk factors for vascular disease. Am. J. Ther. 2010, 17, 125–132. 
86.  Andersen, L.P.; Holck, S.; Kupcinskas, L.; Kiudelis, G.; Jonaitis, L.; Janciauskas, D.; Permin, H.; 
Wadstrom, T. Gastric inflammatory markers and interleukins in patients with functional dyspepsia 
treated with astaxanthin. FEMS Immunol. Med. Microbiol. 2007, 50, 244–248. Mar. Drugs 2011, 9  
 
 
465 
87.  Fassett, R.G.; Healy, H.; Driver, R.; Robertson, I.K.; Geraghty, D.P.; Sharman, J.E.; Coombes, J.S. 
Astaxanthin vs. placebo on arterial stiffness, oxidative stress and inflammation in renal transplant 
patients (Xanthin): A randomised controlled trial. BMC Nephrol. 2008, 9, 17. 
Samples Availability: Available from the authors. 
©  2011  by  the  authors;  licensee  MDPI,  Basel,  Switzerland.  This  article  is an open  access  article 
distributed  under  the  terms  and  conditions  of  the  Creative  Commons  Attribution  license 
(http://creativecommons.org/licenses/by/3.0/). 